Invention Grant
- Patent Title: Radiolabeled Darapladib and analogs thereof and their use as imaging compounds
-
Application No.: US16650532Application Date: 2018-09-26
-
Publication No.: US11583596B2Publication Date: 2023-02-21
- Inventor: Olivier Meilhac , Emmanuelle Jestin , Florian Guibbal , Sébastien Benard
- Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE LA REUNION
- Applicant Address: FR Paris; FR Saint Denis
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITE DE LA REUNION
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITE DE LA REUNION
- Current Assignee Address: FR Paris; FR Saint Denis
- Agency: WCF IP
- Priority: EP17306272 20170926
- International Application: PCT/EP2018/076163 WO 20180926
- International Announcement: WO2019/063634 WO 20190404
- Main IPC: A61K49/04
- IPC: A61K49/04 ; A61K51/04 ; C07D239/95 ; C07D403/06 ; C07D405/12 ; C07F5/02 ; A61K9/00
Abstract:
The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
Public/Granted literature
- US20200276337A1 RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS Public/Granted day:2020-09-03
Information query
